ENGN

+ Watchlist + Portfolio

enGene Holdings Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.98
52-Week Range: $1.40 – $12.25
Market Cap: $130.01M
P/E (TTM): —
EPS (TTM): -2.07
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.56
PEG Ratio: —
Return on Equity: -60.50%
Return on Assets: -32.00%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 10.21
Debt/Equity: 0.14
Total Debt: $33.27M
Free Cash Flow: $-60.85M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-103.04M

ENGN Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$15.47M	$16.46M	$38.31M	$94.48M
Selling, General & Admin	$3.26M	$8.47M	$23.98M	$28.68M
Operating Expenses	$19.43M	$26.06M	$62.30M	$123.17M
Operating Income	-$19.43M	-$26.06M	-$62.30M	-$123.17M
EBITDA	-$22.78M	-$94.77M	-$52.04M	-$113.80M
Pretax Income	-$24.44M	-$99.90M	-$55.16M	-$117.30M
Income Tax	$22.00K	$17.00K	-$19.00K	$0.00
Net Income	-$24.46M	-$99.92M	-$55.14M	-$117.30M
Diluted EPS	-1.25	-4.52	-1.46	-2.29
Diluted Shares	23.20M	23.20M	37.78M	51.12M

ENGN Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$20.43M	$81.52M	$173.00M	$50.15M
Receivables	$1.34M	$2.34M	$332.00K	$927.00K
Current Assets	$22.58M	$85.44M	$247.36M	$201.39M
Total Assets	$23.91M	$86.96M	$311.17M	$221.47M
Current Liabilities	$5.10M	$5.26M	$14.66M	$31.98M
Long-Term Debt	$30.84M	$9.22M	$22.47M	$15.32M
Total Debt	$32.11M	$9.78M	$25.02M	$31.80M
Total Liabilities	$47.41M	$14.47M	$38.56M	$53.76M
Retained Earnings	-$99.67M	-$199.59M	-$254.73M	-$372.03M
Shareholders' Equity	-$23.50M	$72.49M	$272.61M	$167.71M
Working Capital	$17.48M	$80.18M	$232.70M	$169.41M
Net Debt	$11.68M	—	—	—

ENGN Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$17.59M	-$24.74M	-$48.28M	-$99.24M
Capital Expenditure	-$153.00K	-$318.00K	-$925.00K	-$1.49M
Free Cash Flow	-$17.75M	-$25.06M	-$49.21M	-$100.72M
Depreciation & Amortisation	$238.00K	$175.00K	$323.00K	$509.00K
Stock-Based Compensation	$116.00K	$3.45M	$5.32M	$9.65M
Investing Cash Flow	-$153.00K	-$318.00K	-$125.95M	-$25.14M
Financing Cash Flow	$27.97M	$86.15M	$265.72M	$1.52M
Net Change in Cash	$10.22M	$61.09M	$91.48M	-$122.85M

ENGN Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$20.21M	$22.57M	$31.72M	$22.25M	$22.20M	$20.09M
Selling, General & Admin	$6.92M	$7.37M	$10.02M	$8.93M	$9.77M	$13.92M
Operating Expenses	$27.12M	$29.95M	$39.48M	$31.18M	$31.97M	$34.01M
Operating Income	-$27.12M	-$29.95M	-$39.48M	-$31.18M	-$31.97M	-$34.01M
EBITDA	-$24.73M	-$27.86M	-$37.46M	-$28.83M	-$29.30M	-$31.48M
Pretax Income	-$25.57M	-$28.75M	-$38.38M	-$29.75M	-$30.23M	-$32.50M
Income Tax	$240.00K	$239.00K	-$497.00K	$0.00	$0.00	$0.00
Net Income	-$25.82M	-$28.99M	-$37.88M	-$29.75M	-$30.23M	-$32.50M
Diluted EPS	-0.51	-0.57	—	-0.44	-0.43	-0.47
Diluted Shares	51.02M	51.10M	—	67.26M	69.72M	69.73M

ENGN Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Cash & Equivalents	$57.55M	$32.62M	$50.15M	$36.61M	$29.83M	$41.02M
Receivables	$533.00K	$709.00K	$927.00K	$1.20M	$822.00K	$975.00K
Current Assets	$227.97M	$211.31M	$201.39M	$289.22M	$270.00M	$277.90M
Total Assets	$266.65M	$245.55M	$221.47M	$337.11M	$307.52M	$288.32M
Current Liabilities	$18.00M	$20.44M	$31.98M	$24.61M	$21.48M	$27.21M
Long-Term Debt	$20.02M	$17.71M	$15.32M	$24.74M	$24.91M	$25.16M
Total Debt	$25.36M	$31.38M	$31.80M	$33.46M	$33.35M	$33.27M
Total Liabilities	$39.36M	$44.88M	$53.76M	$55.57M	$52.36M	$58.03M
Retained Earnings	-$305.16M	-$334.15M	-$372.03M	-$401.78M	-$432.01M	-$464.51M
Shareholders' Equity	$227.29M	$200.67M	$167.71M	$281.55M	$255.17M	$230.29M
Working Capital	$209.97M	$190.87M	$169.41M	$264.61M	$248.51M	$250.69M

ENGN Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Operating Cash Flow	-$22.95M	-$25.63M	-$24.96M	-$28.90M	-$30.50M	-$18.95M
Capital Expenditure	-$45.00K	-$704.00K	-$437.00K	-$153.00K	-$98.00K	—
Free Cash Flow	-$22.99M	-$26.34M	-$25.40M	-$29.06M	-$30.60M	-$18.95M
Depreciation & Amortisation	$106.00K	$130.00K	$171.00K	$189.00K	$180.00K	$178.00K
Stock-Based Compensation	$2.65M	$2.58M	$2.61M	$2.80M	$4.14M	$7.81M
Investing Cash Flow	$17.95M	$1.38M	$40.50M	-$126.30M	$23.64M	$30.12M
Financing Cash Flow	$199.00K	-$667.00K	$1.99M	$141.66M	$74.00K	$23.00K
Net Change in Cash	-$4.80M	-$24.92M	$17.53M	-$13.54M	-$6.79M	$11.20M

Market Snapshot

About

enGene Holdings Inc. is a clinical-stage biotechnology company developing non-viral, DNA-based gene therapies for cancer and other diseases. The company's proprietary defiNGene platform delivers therapeutic genes directly to target tissues using a transient delivery system. Their lead program focuses on treating bladder cancer through localized gene therapy administration. enGene is advancing multiple candidates through preclinical and clinical development stages.